Encision, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Mar 31, 2025 was Product at $6.2 million, 95% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2025
|
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
FY 2021
Mar 31, 2021
|
FY 2020
Mar 31, 2020
|
FY 2019
Mar 31, 2019
|
FY 2018
Mar 31, 2018
|
FY 2017
Mar 31, 2017
|
FY 2016
Mar 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6
|
7
|
7
|
7
|
8
|
8
|
8
|
9
|
9
|
9
|
9
|
| Product |
6
-5.8%
share 94.4%
|
6
-3.3%
share 94.8%
|
6
-6.6%
share 97.7%
|
7
-0.4%
share 93.7%
|
7
share 90.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Services |
0
+95.5%
share 5.6%
|
0
+119.4%
share 5.2%
|
0
-66.8%
share 2.3%
|
0
-38.5%
share 6.3%
|
1
share 9.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ECIA (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- CO
- Headquarters
- Boulder, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 930775
- Former names
- ELECTROSCOPE INC (until Aug 1, 2000)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.